Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Hits New 12-Month High – Should You Buy?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $11.23 and last traded at $11.02, with a volume of 34213 shares trading hands. The stock had previously closed at $11.15.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. KGaA in a research report on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Performance

The company has a market cap of $24.62 billion, a price-to-earnings ratio of 52.48 and a beta of 1.02. The firm has a 50-day simple moving average of $9.87 and a 200 day simple moving average of $9.36. The company has a quick ratio of 1.05, a current ratio of 1.36 and a debt-to-equity ratio of 0.57.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last announced its earnings results on Wednesday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $6.01 billion for the quarter. On average, sell-side analysts predict that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current fiscal year.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.